富士胶片：向外部授予iPS单元专利：Lonza Walkersville，Inc.。
富士胶卷：
FUJIFILM细胞动力学：
美国子公司拥有iPS电池的专利。
“用于测试候选药物安全性和有效性的IPS细胞”正在销售中。
iPS细胞的产生：
生产iPS细胞的方法多种多样，但据说Fujifilm的专利技术是高度安全的。
此外，只有少数公司/组织可以生产治疗性iPS细胞。
直到现在，Fujifilm仍将“治疗性iPS细胞的销售和专利”仅限于具有资本关系的公司。
授予专利许可：
最近，它决定向外部授予专利许可，并且第一步，它已将使用许可授予Ronza的美国子公司。
授予治疗性iPS细胞生产的专利，用于开发再生医学产品。
Fujifilm从Ronza获得了许可收入，但未披露金额。
除了Ronza以外，“来自十几家公司的询问”（富士电影公司）。
治疗性iPS细胞的外部销售：
开始销售用于治疗的iPS细胞。
尽管针对血液癌和骨髓移植并发症的临床试验正在进行中，但使用iPS细胞的再生医学产品尚未投入实际使用。
美国BCC研究：
iPS电池的全球市场预计将从2019年的24亿美元增长到2024年的38亿美元。
富士胶片通过在细胞培养中利用“照相胶片中培养的拼贴技术”进入再生医学领域。
该政策的重点是iPS电池的外部销售，许可和合同制造。
再生医疗产品的代工生产：
2020年3月，治疗性iPS细胞生产设施在美国投入运营。
将来，我们的目标是成为使用iPS细胞进行再生医学产品合同制造的世界领导者。
日本经济新闻
https://www.nikkei.com/article/DGXMZO66135010S0A111C2XB0000/
FUJIFILM Cellular Dynamics and Lonza agree to expand the availability and use of induced pluripotent stem cell technology
FUJIFILM Cellular Dynamics and Lonza
agree to expand the availability and use of induced pluripotent stem cell technology – FUJIFILM Cellular Dynamics grants Lonza
a non-exclusive right to use their patents related to iPSC generation,
including episomal vectors and reprogramming factors, for development and clinical manufacture of iPSC lines for cell therapies
– Lonza grants FUJIFILM Cellular Dynamics expanded use of its non-exclusive license to its innovative Nucleofector™ technology –
The agreement enables drug developers
to leverage both companies expertise and technologies for the generation of human-induced pluripotent stem cells through licensing agreements MADISON, Wis., and WALKERSVILLE, Md.,
November , 2020 — FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC) technologies, and Lonza Walkersville, Inc. (Lonza, a leading global GMP iPSC manufacturer),
have entered into a worldwide agreement. The agreement enables drug developers to leverage both companies’ expertise and technologies for the generation of iPSCs through licensing agreements.
Under the agreement,
FUJIFILM Cellular Dynamics
grants Lonza a non-exclusive right to use their patents related to iPSC generation, including episomal vectors and reprogramming factors, for the clinical manufacture and differentiation of iPSC lines for cell therapies.
Furthermore, Lonza grants FUJIFILM Cellular Dynamics expanded use of its non-exclusive license to its innovative Nucleofector™ technology, to enable efficient transfection of cells, stem cell and cell lines.
Cell therapies
have emerged as a promising treatment modality with the ability to augment, repair, or replace human biology, including organs, tissues and cells.
Given their incredible capacity to self-renew and the ability to become many different cell types, iPSCs are a critical material used in the development and manufacture of cell therapies.
FUJIFILM Cellular Dynamics
is a key global player with the technology and expertise in iPSC episomal generation enabling high quality, purity and reproducibility,” said Takeshi Yamamoto, chief executive officer, FUJIFILM Cellular Dynamics.
We are pleased to reach this outcome with Lonza to produce iPSC lines to better serve drug developers.
We expect to grant additional patent licenses to pharmaceutical and biotech companies to support the growth of available cell therapies.
As true leaders in our field, both companies came to an agreement which benefits our customers and brings clarity to the industry.” said Alberto Santagostino, SVP, Head of Cell and Gene Technologies, Lonza.
It shows our common goal to make high quality iPSC therapies available at affordable cost to our customers.
Additionally, we are pleased to expand the license-use of our innovative Nucleofector™ technology granted to FUJIFILM Cellular Dynamics.
This agreement further strengthens our leading end-to-end proprietary service offering for iPSCs.
In combination with Lonza’s L7™ hPSC Culture System and non-viral 4D-Nucleofector™ Transfection Technology, this represents an excellent approach for reprogramming and culturing GMP grade iPSCs”
Fujifilm Global